Drugs / Tirolizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06284746 | Oct 2023 → Apr 2025 | Her2-receptor negative breast cancer, gastric carcinoma | Lin Chen | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tirolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06284746 ↗ |